Medtronic and Philips partner to upskill 300+ Clinicians in Structural Heart Imaging in India

The training program will combine didactic sessions with hands-on experience delivered on Philips’ cutting-edge ultrasound and MRI systems, under the guidance of renowned international and Indian experts. 15 key medical institutions have been identified specialising in structural heart procedures for these educational workshops.

Speaking on the collaboration Mandeep Singh Kumar, Managing Director and Vice President of Medtronic India said, “We are excited to partner with Philips to bring this innovative training initiative to life. This collaboration represents a significant step forward in our ongoing commitment to improving patient outcomes, particularly for those with chronic kidney disease and ESRD. By providing specialised training and advanced imaging solutions, we aim to equip healthcare professionals with the tools they need to enhance the precision of TAVI (Transcatheter Aortic Valve Implantation) procedures and ultimately improve patient care."

“At Philips, every effort we make is centered on providing better care for more people and this partnership with Medtronic is another step towards our goal. By focusing on innovation and education in structural heart imaging across India, we aim to address the rapid advancements in multi-modality imaging through continuous learning. Our objective is to empower clinicians with advanced techniques such as echocardiography and MRI, leading to more accurate diagnoses and improved care outcomes, especially for ESRD patients”, said Bharath Sesha, Managing Director, Philips Indian Subcontinent. “As India's healthcare landscape progresses to address its high disease burden, we remain committed to enhancing clinical expertise and making a meaningful impact on patient care”. 

With the rising incidence of Chronic Kidney Disease (CKD) in India, adding approximately 2.2 lakh* new cases of ESRD each year, and global studies** indicating that 9.5% of ESRD patients with Aortic Stenosis can benefit from advanced imaging technologies during Transcatheter Aortic Valve Replacement (TAVR), there is a critical need for advanced diagnostic solutions and specialised training for clinicians.

Medtronic transcatheter aortic valve replacement (TAVR) system recently celebrated a significant milestone: 20 years since its first-in-human procedure in 2004. This landmark achievement underscores Medtronic's unwavering commitment to continuous innovation and commercialisation in the field of cardiovascular care. Over the past two decades, Medtronic has introduced a series of groundbreaking TAVR systems in India, consistently pushing the boundaries of minimally invasive heart valve replacement and improving patient outcomes. 

Philips's AI-driven software, capable of analysing aortic anatomy using data obtained from 3D transesophageal echocardiography (3D TEE) and MRI, eliminates the need for radiopaque contrast agents. This innovation is particularly advantageous for safeguarding kidney health, as contrast agents can be nephrotoxic and pose a significant risk of further deteriorating kidney function in ESRD patients. By enabling clinicians to use alternate imaging approaches, the partnership will significantly improve both the duration and quality of life for these patients.

*Source - Introduction of Pradhan Mantri National Dialysis Program (PMNDP)

**Source - https://pubmed.ncbi.nlm.nih.gov/36812906/ 

For further information, please contact:

Medtronic

Masooma Pathre

masooma.pathre@medtronic.com 

Philips

Gunjan Mukherjee

gunjan.mukherjee@philips.com

About Medtronic 

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn. 

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. All details contained in this release are for general awareness purposes only and do not constitute medical advice. 

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.